NOTE: As provided in LFC policy, this report is
intended only for use by the standing finance committees of the
legislature. The Legislative Finance Committee does not assume
responsibility for the accuracy of the information in this report when used for
other purposes.
The most recent FIR
version (in HTML & Adobe PDF formats) is available on the Legislative
Website. The Adobe PDF version includes
all attachments, whereas the HTML version does not. Previously issued FIRs and attachments may be
obtained from the LFC in
SPONSOR: |
Begaye |
DATE TYPED: |
|
HB |
648 |
||
SHORT TITLE: |
Medical and Clinical Services for Seniors |
SB |
|
||||
|
ANALYST: |
Hayes |
|||||
APPROPRIATION
Appropriation
Contained |
Estimated
Additional Impact |
Recurring or
Non-Rec |
Fund Affected |
||
FY03 |
FY04 |
FY03 |
FY04 |
|
|
|
$400.0 |
|
|
Nonrecurring |
General
Fund |
|
|
|
|
|
|
(Parenthesis
( ) Indicate Expenditure Decreases)
Relates
to HB384 and SB 338
Responses
Received From
State
Agency on Aging
Department
of Health (DOH)
SUMMARY
Synopsis
of Bill
House Bill 648 appropriates
$400.0 to the State agency on Aging from the general fund to conduct a pilot
project to provide medication evaluations and pharmacist clinical services to
seniors and to develop and implement collection and aggregate data reporting on
the effectiveness and benefit of this service to seniors.
Significant
Issues
1. Seniors and the disabled
population are paying the highest out-of-pocket costs for medications in
2. Although pharmacists are
required to provide clinical services to individuals, many people who could
most benefit from the services do not visit their local pharmacists for an
evaluation of their drug regimen. With increasing
reliance on prescription drugs as a means of treatment, medication management
and pharmacy clinical services are growing more important.
3. HB 648 would allow the
State Agency on Aging to identify affordable drug programs by using the services
of clinical pharmacists to assist and implement drug management systems for
seniors. Pharmacists are highly
qualified to identify and recommend low cost generic prescription drugs or less
expensive brands instead of higher priced brand name drugs. Many of the generic drugs produced today are
equal to or superior to many of the brand name drugs. Pharmacists will be allowed to collect and
aggregate data obtained from
4. HJM 22 (2001
Legislature) requested that the Health Policy Commission conduct a study to
examine the impact of rising prescription drug costs and to develop recommendations
for addressing this issue. An advisory
committee was formed and one of the recommendations made includes: “The committee believed that educating consumers
on the medications they were taking is crucial to assure optimal health benefits
while recognizing that pharmacists often did not have sufficient time to provide
the necessary consultation.” (p. 30, HPC
HJM 22 report, October 2002). HB 648
seeks to address this issue by developing a mechanism so that seniors can
access clinical pharmacy services, including an evaluation of all the medications
they are taking.
FISCAL IMPLICATIONS
The appropriation of
$400.0 contained in this bill is a non-recurring expense to the general
fund. Any unexpended or unencumbered
balance remaining at the end of fiscal year 2004 shall revert to the general
fund.
ADMINISTRATIVE IMPLICATIONS
The
State Agency on Aging anticipates no additional staffing needs to carry out the
requirements of HB 648 since
the appropriation would be passed through the agency to a qualified entity. There will be administrative costs for the
designated entity to design the project, collect documentation for reimbursements
and pay the reimbursement requests.
RELATIONSHIP
HB384 and SB 338,
Medicaid Reform Committee Recommendations, include language to direct HSD to
review policies to ensure pharmacists have the flexibility for and are not
discouraged from using generic drug when a generic or a low-cost equivalent is
available. In addition, these two bills
direct HSD to examine and provide an analysis of methods of reducing costs and
providing clinical pharmacy services to Medicaid recipients.
OTHER SUBSTANTIVE
ISSUES
While HB 648 directs
the State Agency on Aging “to develop and implement collection and aggregate
data reporting on the effectiveness and benefit of these services to seniors,”
it is unclear how the pilot project as a whole will be evaluated. As a “pilot project,” this analysis assumes
that funding is non-recurring. In order
to continue the project in future fiscal years, data may need to be presented
to the Legislature regarding the success or failure of the project. At that time, additional funding for the
project’s continuance could be considered.
In the meantime, HB 648 may need to clarify how such an evaluation
should be conducted. Developing
additional performance measures may assist in determining the project’s
accomplishments and outcome.
CMH/njw